Delving into the Latest Updates on Mesenchymal stem cells for blood purification (Guangdong Qianhui) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

QH-863-3

Target-

Action-

Mechanism

Stem cell replacements

Therapeutic Areas

Digestive System DisordersOther Diseases

Active Indication

Acute-On-Chronic Liver Failure

Inactive Indication-

Originator Organization

Guangdong Qianhui Biotechnology Co., Ltd.

Active Organization

Guangdong Qianhui Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

To evaluate the safety and effectiveness of the combined bioartificial liver therapy device QH-1A and mesenchymal stem cells for blood purification in the treatment of chronic acute liver failure, and to confirm the recommended treatment time and frequency for Phase II; to evaluate the immunogenicity of mesenchymal stem cell therapy for blood purification

Start Date07 May 2025

Sponsor / Collaborator

Guangdong Qianhui Biotechnology Co., Ltd.

100 Clinical Results associated with Mesenchymal stem cells for blood purification (Guangdong Qianhui)

Login to view more data

100 Translational Medicine associated with Mesenchymal stem cells for blood purification (Guangdong Qianhui)

Login to view more data

100 Patents (Medical) associated with Mesenchymal stem cells for blood purification (Guangdong Qianhui)

Login to view more data

100 Deals associated with Mesenchymal stem cells for blood purification (Guangdong Qianhui)

Login to view more data